Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
GV20 received an upfront payment and is eligible for additional milestone payments
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
It is the first autotaxin inhibitor to be investigated in cancer patients
APAC region contributed around 50% of the in-vitro diagnostics market in 2022
The company will manufacture a cancer immunotherapy product from 2022
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Subscribe To Our Newsletter & Stay Updated
